Download Developing Therapeutics for Alzheimer’s Disease Ebook PDF

Developing Therapeutics for Alzheimer's Disease

Developing Therapeutics for Alzheimer's Disease
Progress and Challenges

by Michael S. Wolfe

  • Publisher : Academic Press
  • Release : 2016-05-27
  • Pages : 676
  • ISBN : 0128021640
  • Language : En, Es, Fr & De
GET BOOK

Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics. Provides a realistic but promising assessment of the potential of various therapeutic approaches to Alzheimer’s disease Focuses primarily on neuroprotective agents and cognitive enhancers, as well as approaches to targeting the amyloid B-peptide, tau and Apolipoprotein E Discusses alternative approaches, preclinical and clinical development issues, related biomarkers and diagnostics, and prevention and nonpharmacological approaches

Pharmacological Mechanisms in Alzheimer's Therapeutics

Pharmacological Mechanisms in Alzheimer's Therapeutics
A Book

by A. Claudio Cuello

  • Publisher : Springer Science & Business Media
  • Release : 2007-12-22
  • Pages : 324
  • ISBN : 0387715223
  • Language : En, Es, Fr & De
GET BOOK

The need for effective therapy to treat Alzheimer’s disease is greater than ever, but there is still no drug therapy that can stop or reverse the progression of the disease. There is, however, a great deal of anticipation over the imminent development of effective therapies as a result of the identification of promising targets for drug development. This book investigates these targets and examines ongoing strategies to develop effective therapies for this devastating neurodegenerative condition.

BACE

BACE
Lead Target for Orchestrated Therapy of Alzheimer's Disease

by Varghese John

  • Publisher : John Wiley & Sons
  • Release : 2010-03-05
  • Pages : 272
  • ISBN : 9780470594070
  • Language : En, Es, Fr & De
GET BOOK

BACE inhibitors and their use in the treatment of Alzheimer's Disease BACE (β-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery. This book details the story of the discovery of BACE and its role in AD and comprehensively discusses: The development of BACE inhibitors as therapeutics for Alzheimer's disease The research that led to the identification of BACE New BACE inhibitors currently being clinically tested ADME (absorption, distribution, metabolism, excretion) and clinical trial design—topics not addressed in current field literature Cutting-edge technology such as high-throughput screening, structure-based drug design, and QSAR in context of BACE inhibitors and Alzheimer's drug discovery Other approaches to BACE inhibition based on interaction with the precursor protein APP By enhancing the reader's understanding of the various aspects of the BACE drug-discovery process, this much-needed reference will serve as a key resource for all scientists involved in Alzheimer's research—and inspire new approaches to treatment of AD.

Neurofibrillary Tangles as a Target for Developing New Therapeutics for Alzheimer's Disease

Neurofibrillary Tangles as a Target for Developing New Therapeutics for Alzheimer's Disease
A Book

by Howard M. Fillit,Lorenzo M. Refolo

  • Publisher : Unknown Publisher
  • Release : 2002
  • Pages : 97
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Imaging in CNS Drug Discovery and Development

Imaging in CNS Drug Discovery and Development
Implications for Disease and Therapy

by David Borsook,Lino R. Beccera,Edward Bullmore,Richard J. Hargreaves

  • Publisher : Springer Science & Business Media
  • Release : 2010-03-10
  • Pages : 396
  • ISBN : 1441901345
  • Language : En, Es, Fr & De
GET BOOK

Drug development today needs to balance agility, speed, and risk in defining probability of success for molecules, mechanisms, and therapeutic concepts. New techniques such as fMRI promise to be part of a sequence that could transform drug development. Although numerous review articles exist that discuss the use of imaging in drug development, no one source is available that combines the various techniques and includes a discussion of disease mapping. Imaging in CNS Drug Discovery and Development, Implications for Disease and Therapy will serve to distill the most salient developments in the use of imaging in drug development and disease mapping. It will launch evolving concepts that integrate new imaging technologies and paradigms with molecular medicine and molecular profiling ("monics") as well as consider the ethical issues that arise as a result of disease or state diagnosis and the use of imaging in the public eye.

Neurotherapeutics in the Era of Translational Medicine

Neurotherapeutics in the Era of Translational Medicine
A Book

by Richard A. Smith,Brian K. Kaspar,Clive N. Svendsen

  • Publisher : Academic Press
  • Release : 2020-11-28
  • Pages : 518
  • ISBN : 0128172746
  • Language : En, Es, Fr & De
GET BOOK

For the first time in history, there is now hope for treating neurological disorders that had previously been considered untreatable. The remarkable confluence of events that has heralded this is the focus of Neurotherapeutics in the Era of Translational Medicine. This anthology, written by many of the prominent scientists and researchers in the field of biotechnology, recounts the breathtaking advances that are revolutionizing treatment for disorders such as amyotrophic lateral sclerosis‎, spinal muscular atrophy, multiple sclerosis, Parkinson’s disease, myasthenia gravis, migraine, and glioblastoma. The "story behind the story" of these translational efforts is told, with authors depicting the ups and downs encountered on the path of their drug discovery and development effort. In parallel with this path, advances in identifying novel biomarkers and disease models are summarized, as are contemporary issues focusing on clinical trial design, bioethics, innovative funding strategies, and collaborations between government and academia in an effort to facilitate breakthrough treatments. The book is written by members of the biotech and pharmaceutical ecosystem for those who belong to it and aspire to become part of it. Comprehensive review on the progress of translational research in neurotherapeutics for neurologic disorders Discusses important issues in clinical trials such as design and ethical issues Written for neuroscientists, neurologists and pharmacologists

Alzheimer's Disease

Alzheimer's Disease
Understanding Biomarkers, Big Data, and Therapy

by Ahmed A. Moustafa

  • Publisher : Academic Press
  • Release : 2021-08-28
  • Pages : 254
  • ISBN : 0128213353
  • Language : En, Es, Fr & De
GET BOOK

Nearly 44 million people have Alzheimer’s or related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia. First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer’s disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer’s diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer’s disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. Reviews recent developments of cognitive and clinical studies Covers factors underlying the transition from mild cognitive impairment to Alzheimer’s disease Discusses different neural biomarkers underlying the development and treatment of Alzheimer’s disease Provides a comparison of the effectiveness of various types of treatments

Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy

Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy
A Book

by M.C. Carrillo,H. Hampel

  • Publisher : Karger Medical and Scientific Publishers
  • Release : 2012-04-23
  • Pages : 200
  • ISBN : 3805598033
  • Language : En, Es, Fr & De
GET BOOK

Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer’s disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel framework of the disease presented here highlights research on biological markers as well as efforts to validate technologies for early and accurate detection. It also introduces notion of a complex systems dysfunction that extends beyond prevailing ideas derived from the ‘amyloid’ or ‘tau’ hypotheses.This outstanding publication provides researchers, clinicians, students and other professionals interested in neurodegenerative disorders with a comprehensive update on current trends and future directions in therapy development, with special focus on advances in clinical trial designs.

Development of Antibody-Based Therapeutics

Development of Antibody-Based Therapeutics
Translational Considerations

by Mohammad A. Tabrizi,Gadi G. Bornstein,Scott L. Klakamp

  • Publisher : Springer Science & Business Media
  • Release : 2012-04-24
  • Pages : 426
  • ISBN : 1441959556
  • Language : En, Es, Fr & De
GET BOOK

Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in "relevant" animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics.

Design of Hybrid Molecules for Drug Development

Design of Hybrid Molecules for Drug Development
A Book

by Michael Decker

  • Publisher : Elsevier
  • Release : 2017-04-05
  • Pages : 352
  • ISBN : 0081011180
  • Language : En, Es, Fr & De
GET BOOK

Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed. Drawing on practical case studies, the hybridization of molecules for development as treatments for a number of key diseases is then outlined, including the design of hybrids for Alzheimer's, cancer, and malaria. With its cutting-edge reviews of breaking developments in this exciting field, the book offers a novel approach for all those working in the design, development, and administration of drugs for a range of debilitating disorders. Highlights an approach unimpaired by the limitations of the classical search for lead structures - one of the core problems in modern drug development processes, making the content of high relevance for both academic and non-academic drug development processes Pulls together research and design techniques in a novel way to give researchers the best possible platform from which to review the approaches and techniques applied Compares the advantages and disadvantages of these compounds Includes the very latest developments, such as photoactivatable and photo-responsive drugs

Global Clinical Trials for Alzheimer's Disease

Global Clinical Trials for Alzheimer's Disease
Design, Implementation, and Standardization

by Menghis Bairu,Michael Weiner

  • Publisher : Academic Press
  • Release : 2013-08-28
  • Pages : 432
  • ISBN : 0124115306
  • Language : En, Es, Fr & De
GET BOOK

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer’s disease. Written by leading experts with hands-on experience in designing and running global Alzheimer’s disease and other neurodegenerative diseases clinical trials A step-by-step guide that provides critical information on the design, conduct and standardization necessary to effectively execute clinical trials and accelerate drug development in this area Includes practical examples, ethical considerations, lessons learned and other valuable tools to aid the planning and implementation of Alzheimer’s disease global clinical trials in emerging markets and developing countries

Alzheimer's Disease

Alzheimer's Disease
Advances in Etiology, Pathogenesis and Therapeutics

by Khalid Iqbal,Sangram S. Sisodia,Bengt Winblad

  • Publisher : John Wiley & Sons
  • Release : 2003-01-24
  • Pages : 888
  • ISBN : 0470851740
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer's Disease is an ever present problem affecting millions of people around the world and, as people's average lifespan lengthens, its prevalence is set to increase. A global effort is needed to combat the disease, including research to investigate the causes, development of effective treatments and, ultimately, prevention of the disease. Published every two years, these timely books discuss the very latest research. This new volume provides a unique source of reference to the important work being done in this field, it gives academics and clinicians an opportunity to learn about cutting edge developments and covers all aspects of Alzheimer's Disease, including diagnosis, clinical course, epidemiological course and therapeutics and disease mechanisms. Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics will provide essential information for basic and clinical researchers in Alzheimer's Disease and other dementias as well as for those who care for patients.

Accelerating the Development of New Drugs and Diagnostics

Accelerating the Development of New Drugs and Diagnostics
Maximizing the Impact of the Cures Acceleration Network: Workshop Summary

by Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation

  • Publisher : National Academies Press
  • Release : 2012-11-23
  • Pages : 132
  • ISBN : 0309261163
  • Language : En, Es, Fr & De
GET BOOK

Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop.

Drug Discovery and Development for Alzheimer's Disease, 2000

Drug Discovery and Development for Alzheimer's Disease, 2000
A Book

by Howard M. Fillit, MD,Alan W. O'Connell, PhD

  • Publisher : Springer Publishing Company
  • Release : 2002-01-03
  • Pages : 296
  • ISBN : 9780826115348
  • Language : En, Es, Fr & De
GET BOOK

This prestigious volume presents the findings of an international group of academic and biotechnological researchers. Topics range from early detection programs focusing on genetic factors, novel probes for detecting B-amyloid in the living brain, and the use of telephonic screening and MRI's to the diversity of therapeutic areas such as antioxidants, estrogen agonists and various anti-B-amyloid and anti-tangle approaches. The volume is still an indispensable resource for the psychogeriatrician, psychiatrist, clinical investigator, and neurobiologist, and a must for medical libraries.

Improving the Utility and Translation of Animal Models for Nervous System Disorders

Improving the Utility and Translation of Animal Models for Nervous System Disorders
Workshop Summary

by Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders

  • Publisher : National Academies Press
  • Release : 2013-03-25
  • Pages : 110
  • ISBN : 030926636X
  • Language : En, Es, Fr & De
GET BOOK

Nervous system diseases and disorders are highly prevalent and substantially contribute to the overall disease burden. Despite significant information provided by the use of animal models in the understanding of the biology of nervous system disorders and the development of therapeutics; limitations have also been identified. Treatment options that are high in efficacy and low in side effects are still lacking for many diseases and, in some cases are nonexistent. A particular problem in drug development is the high rate of attrition in Phase II and III clinical trials. Why do many therapeutics show promise in preclinical animal models but then fail to elicit predicted effects when tested in humans? On March 28 and 29, 2012, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened the workshop "Improving Translation of Animal Models for Nervous System Disorders" to discuss potential opportunities for maximizing the translation of new therapies from animal models to clinical practice. The primary focus of the workshop was to examine mechanisms for increasing the efficiency of translational neuroscience research through discussions about how and when to use animal models most effectively and then best approaches for the interpretation of the data collected. Specifically, the workshop objectives were to: discuss key issues that contribute to poor translation of animal models in nervous system disorders, examine case studies that highlight successes and failures in the development and application of animal models, consider strategies to increase the scientific rigor of preclinical efficacy testing, explore the benefits and challenges to developing standardized animal and behavioral models. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary also identifies methods to facilitate development of corresponding animal and clinical endpoints, indentifies methods that would maximize bidirectional translation between basic and clinical research and determines the next steps that will be critical for improvement of the development and testing of animal models of disorders of the nervous system.

Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease

Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease
Non-Pharmacological Therapies for Alzheimer's Disease

by Ghulam Md Ashraf,Athanasios Alexiou

  • Publisher : Springer Nature
  • Release : 2019-12-16
  • Pages : 293
  • ISBN : 9811396361
  • Language : En, Es, Fr & De
GET BOOK

This book discusses the latest research into the highly prevalent neurodevelopmental disease most commonly associated with aging: Alzheimer’s disease (AD). Even after years of research, Alzheimer’s disease is still far from being cured. It presents a range of common symptoms in the form of behavioral and cognitive impairments. This book describes the symptoms and the biology behind them. The contents covers latest findings on the genetics involved and various factors and pathways influencing disease development. It also covers various non-pharmacological therapies like immunotherapy, use of natural products, and employing nanotechnology in both the detection and treatment of AD. This book also highlights the role of diet and nutrition in healthy aging. Given its scope, it offers a valuable asset for researchers and clinicians alike.

Biometals in Neurodegenerative Diseases

Biometals in Neurodegenerative Diseases
Mechanisms and Therapeutics

by Anthony R. White,Michael Aschner,Lucio G. Costa,Ashley I. Bush

  • Publisher : Academic Press
  • Release : 2017-04-28
  • Pages : 462
  • ISBN : 0128045639
  • Language : En, Es, Fr & De
GET BOOK

Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics is an authoritative and timely resource bringing together the major findings in the field for ease of access to those working in the field or with an interest in metals and their role in brain function, disease, and as therapeutic targets. Chapters cover metals in Alzheimer’s Disease, Parkinson’s Disease, Motor Neuron Disease, Autism and lysosomal storage disorders. This book is written for academic researchers, clinicians and advanced graduate students studying or treating patients in neurodegeneration, neurochemistry, neurology and neurotoxicology. The scientific literature in this field is advancing rapidly, with approximately 300 publications per year adding to our knowledge of how biometals contribute to neurodegenerative diseases. Despite this rapid increase in our understanding of biometals in brain disease, the fields of biomedicine and neuroscience have often overlooked this information. The need to bring the research on biometals in neurodegeneration to the forefront of biomedical research is essential in order to understand neurodegenerative disease processes and develop effective therapeutics. Authoritative and timely resource bringing together the major findings in the field for those with an interest in metals and their role in the brain function, disease, and as therapeutic targets Written for academic researchers, clinicians and advanced graduate students studying, or treating, patients in neurodegeneration, neurochemistry, neurology and neurotoxicology Edited by international leaders in the field who have contributed greatly to the study of metals in neurodegenerative diseases

Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders

Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders
Workshop Summary

by Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation,Forum on Neuroscience and Nervous System Disorders

  • Publisher : National Academies Press
  • Release : 2015-10-22
  • Pages : 128
  • ISBN : 0309373263
  • Language : En, Es, Fr & De
GET BOOK

The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop.

Alzheimer's Disease

Alzheimer's Disease
Targets for New Clinical Diagnostic and Therapeutic Strategies

by Renee D. Wegrzyn,Alan S. Rudolph

  • Publisher : CRC Press
  • Release : 2012-04-26
  • Pages : 298
  • ISBN : 1439827087
  • Language : En, Es, Fr & De
GET BOOK

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores: The basis of AD and the role of Aβ oligomers in development of disease Existing and emerging in vitro biomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies In vivo imaging diagnostic approaches Evolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies Recent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective/neurorepair approaches How a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis The molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies The latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.

Treatment Development Strategies for Alzheimer's Disease

Treatment Development Strategies for Alzheimer's Disease
A Book

by Thomas Crook,Raymond T. Bartus,Steven Ferris

  • Publisher : Unknown Publisher
  • Release : 1986
  • Pages : 699
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK